Tariquidar

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Tariquidar
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
ATC codePage Template:Plainlist/styles.css has no content.
  • none
Identifiers
  • N-[2-[[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC38H38N4O6
Molar mass646.744 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC
  • InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43) ☒N
  • Key:LGGHDPFKSSRQNS-UHFFFAOYSA-N ☒N
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Tariquidar (INN/USAN) is a potent P-glycoprotein inhibitor and a substrate of breast cancer protein (BCRP/ABCG2)[1] undergoing research as an adjuvant against multi-drug resistance in cancer.[2]

Tariquidar progressed to phase III clinical trials in combination with vinorelbine in an effort to enhance the efficacy of this chemotherapeutic agent. However, several of these trials were terminated early due to adverse effects, and further development of Tariquidar was subsequently halted.[3]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content.Weidner LD, Fung KL, Kannan P, Moen JK, Kumar JS, Mulder J, et al. (February 2016). "Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 44 (2): 275–282. doi:10.1124/dmd.115.067785. PMC 4746486. PMID 26658428.
  2. ^ Page Module:Citation/CS1/styles.css has no content.Fox E, Bates SE (April 2007). "Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor". Expert Review of Anticancer Therapy. 7 (4): 447–459. doi:10.1586/14737140.7.4.447. PMID 17428165.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Modok S, Mellor HR, Callaghan R (August 2006). "Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer". Current Opinion in Pharmacology. 6 (4): 350–354. doi:10.1016/j.coph.2006.01.009. PMID 16690355.

Template:Asbox

Retrieved from "https://cosmopedia.co/index.php?title=Tariquidar&oldid=5783582"